Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) EPS (Weighted Average and Diluted) (2021 - 2025)

Tango Therapeutics has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at -$0.3 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.3 for Q4 2025, up 11.76% from a year ago — trailing twelve months through Dec 2025 was -$0.88 (up 26.67% YoY), and the annual figure for FY2025 was -$0.87, up 26.89%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.3 at Tango Therapeutics, down from $0.13 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for TNGX hit a ceiling of $0.13 in Q3 2025 and a floor of -$0.36 in Q1 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.29 (2022), compared with a mean of -$0.26.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 211.11% in 2022 and later skyrocketed 148.15% in 2025.
  • Tango Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.26 in 2021, then dropped by 26.92% to -$0.33 in 2022, then grew by 9.09% to -$0.3 in 2023, then dropped by 13.33% to -$0.34 in 2024, then rose by 11.76% to -$0.3 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.3 (Q4 2025), $0.13 (Q3 2025), and -$0.35 (Q2 2025) per Business Quant data.